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ABSTRACT
One mechanism of resistance of prostate cancer (PCa) to enzalutamide 
(MDV3100) treatment is the increased expression of AR variants lacking the ligand 
binding-domain, the best characterized of which is AR-V7. We have previously 
reported that Phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5Kα), is a lipid 
kinase that links to CDK1 and AR pathways. The discovery of PIP5Kα inhibitor 
highlight the potential of PIP5K1α as a drug target in PCa. In this study, we show 
that AR-V7 expression positively correlates with PIP5K1α in tumor specimens from 
PCa patients. Overexpression of AR-V7 increases PIP5K1α, promotes rapid growth 
of PCa in xenograft mice, whereas inhibition of PIP5K1α by its inhibitor ISA-2011B 
suppresses the growth and invasiveness of xenograft tumors overexpressing AR-V7. 
PIP5K1α is a key co-factor for both AR-V7 and AR, which are present as protein-protein 
complexes predominantly in the nucleus of PCa cells. In addition, PIP5K1α and CDK1 
influence AR-V7 expression also through AKT-associated mechanism dependent on 
PTEN-status. ISA-2011B disrupts protein stabilization of AR-V7 which is dependent on 
PIP5K1α, leading to suppression of invasive growth of AR-V7-high tumors in xenograft 
mice. Our study suggests that combination of enzalutamide and PIP5K1α may have 
a significant impact on refining therapeutic strategies to circumvent resistance to 
antiandrogen therapies. 
INTRODUCTION
Although considerable progress is being made to 
improve therapy of PCa, one-third of treated PCa patients 
will experience disease recurrence and will progress 
into castration-resistant PCa (CRPC), which are no 
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longer responsive to anti-androgen therapies [1-4]. One 
mechanism of resistance to antiandrogen treatment is the 
increased expression of AR variants lacking the ligand 
binding-domain, the best characterized of which is AR-
V7 [5-7]. AR-V7 is a constitutive active variant lacking 
the LBD encoded by exon 4-8, owing to utilization of a 
cryptic exon [7]. AR-V7 expression is significantly higher 
in CRPC specimens than in specimens from hormone-
naïve PCa and is associated with worse clinical outcome, 
suggesting an important role of AR-V7 in development of 
CRPC [8, 9].
Enzalutamide inhibits recruitment of AR 
coactivators and prevents AR nuclear localization [10]. 
Although enzalutamide is beneficial for patients with 
metastatic CRPC, giving an increasing in survival [11, 
12], a rapid development of resistance in PCa patients 
to enzalutamide treatment remain to be a major clinical 
challenge [11]. The increased level of AR-V7 transcript 
was detected in circulating tumor cells from PCa patients 
who developed enzalutamide resistance [13]. It is believed 
that AR-V7 lacking the LBD evades enzalutamide, which 
acts via the LBD [11, 14]. However, the AR-V7-mediated 
cellular mechanisms in resistance to enzalutamide remain 
poorly understood. 
Phosphatidylinositol 4-phosphate 5-kinase alpha 
(PIP5K1α) and its phospholipid product PIP2 have 
emerged as a new class of predictive biomarkers and drug 
targets in prostate cancer [15]. PIP5K1α is a lipid kinase 
similar to PI3K and acts on PI3K/AKT/PTEN pathways, 
and thereby regulates cell survival and migration [16]. 
PIP5K1α produces PIP2, a major substrate for triggering 
PI3K/AKT activity which is also regulated by PTEN 
to turn off the over-activated AKT [17]. Related to 
this, alterations in AR and PI3K/AKT/PTEN signaling 
complexes cooperatively contribute to PCa progression 
[18, 19]. We recently described a selective PIP5K1α 
inhibitor, ISA-2011B, which blocks the PI3K/AKT 
pathway by decreasing AKT phosphorylation at Serine 
473 (pAKT S473), and suppresses growth of aggressive 
tumors in xenograft mice [15, 20, 21]. Further, we have 
shown that PIP5K1α cross-interacts with AR, and ISA-
2011B significantly inhibits AR and PSA expression and 
induced apoptotic cell death in LNCaP cells[15]. 
CDK1 is the most essential kinase in CDK family, 
and is sufficient to drive cell division cycle in mammalian 
cells [22]. CDK1 is in complex with cyclin B1 and 
cyclin A, and is a component of the PI3K/AKT kinase 
network. This network is upregulated by extracellular 
chemokines in PCa cells during invasion [23]. Indeed, 
CDK1 phosphorylates AR and thereby enhances AR 
activity during progression of castration resistant PCa 
[24] . However, the precise role of CDK1 in driving PCa 
progression is unclear. 
In the present study, we have studied the role of AR-
V7 and its functional association with PIP5K1α and CDK1 
in PCa progression using PCa cell lines and xenograft 
mouse models. We have further investigated whether the 
PIP5K1α inhibitor, ISA-2011B might suppress the growth 
of AR-V7-overexpressing tumors and selectively block the 
deregulated AR-V7 pathways in xenograft mouse models. 
Our study identifies novel cooperative mechanisms 
involving PIP5K1α, AR-V7, CDK1 and AR, which 
drive tumor progression and contribute to enzalutamide 
resistance. Our findings provide new information to guide 
the development of targeted therapeutic combinations for 
treatment of invasive castration-resistant PCa. 
RESULTS
Expression of AR-V7 and PIP5K1α in primary 
PCa and in PCa metastatic specimens 
To evaluate clinical importance of AR-V7 and its 
correlation with PIP5K1α expression in PCa patients, 
the first sets of tissue microarrays (TMAs) consisting of 
begin prostate hyperplasia (BPH) (n=48), primary PCa 
(n=65), and PCa metastatic tissues (n=43) were immuno-
stained with antibodies against AR-V7 and PIP5K1α. A 
second TMA that contained biopsies of BPH and cancer 
tissues from 48 PCa patients was also examined for AR-
V7 and PIP5K1α expression. AR-V7 expression was 
predominantly nuclear, whereas PIP5K1α expression was 
present in both cytoplasm and nucleus of cancer cells 
(Figure 1a and b). PIP5K1α expression was increased in 
tumors with high level of AR-V7 compared with that of 
tumors with lower AR-V7 expression (p=0.045, Figure 
1c). Metastatic lesions in lymph nodes, lungs and bones 
displayed increased PIP5K1α compared with that of 
primary PCa (p=0.014; Figure 1d and e). Similarly, AR-
V7 expression was also significantly higher in metastasis 
tissues compared with that in primary PCa (p<0.001, 
Figure 1f and g). Thus, elevated level of AR-V7 positively 
correlates with the increased PIP5K1α expression in 
primary PCa tissues. A trend of the correlation between 
AR-V7 and PIP5K1α was also observed in metastatic 
tissues (p=0.056, Figure 1h). We next examined PIP5K1A 
expression in AR-V7 positive or negative primary PCa 
tissues (n=333) using the National Cancer Institute 
database [25]. Although there was no statistically 
significant correlation between AR-V7 and PIP5K1A 
mRNA expression in primary PCa of this patient cohort, 
we observed that PTEN expression was decreased in 
tumors with higher PIP5K1A as compared to those with 
lower PIP5K1A (p=0.011, Figure 1i). Similarly, PTEN 
expression was significantly decreased in AR-V7-positive 
tumors as compared to that in AR-V7-negative tumors (p= 
0.023, Figure 1j). These data suggest that expression of 
AR-V7 and PIP5K1A correlates with PTEN-status in PCa 
patients. 
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Figure 1: Evaluation of the clinical importance of AR-V7 and its correlation with PIP5K1α in PCa patients. 
Immunohistochemical analysis of AR-V7 and PIP5K1α expression on the TMAs that contain BPH, PCa specimens and metastatic PCa 
tissues. (a and b). Representative microphotographs show the expression of AR-V7 and PIP5K1α in BPH, low Gleason score- and high 
Gleason score-tumors. Gleason score lower than 6 was defined as “Low grade”. Tumors with Gleason score greater than 8 were defined as 
“High grade”. Scale bars are indicated. (c). Box-plot quantitative comparison shows that PIP5K1α expression is increased in AR-V7-high 
group (n=9) compared with that in AR-V7-low group (n=36). p= 0.045. (d and f). Representative microphotographs show the expression 
of PIP5K1α and AR-V7 in primary tumor tissues and metastatic tissues including lymph node (LN), lung, and bone. (e and g). Box-plot 
quantitative comparisons of PIP5K1α and AR-V7 expression between primary cancer and metastatic cancer specimens are shown. For 
PIP5K1α, primary PCa: PCa (n=61), and the metastatic tissues: Met (n=41) were compared, p= 0.014. For AR-V7, primary PCa (n=63) and 
metastases (n=40) were compared, p< 0.001. (h). Box-plot quantitative comparison shows that PIP5K1α expression is increased in AR-V7-
high group (n=6) compared with AR-V7-low group (n=50) in metastatic tissues. p= 0.056. (i). Box-plot quantitative comparison shows that 
PTEN mRNA expression is down-regulated in PIP5K1A-High group (n=127) compared with PIP5K1A-Low group (n =163), p= 0.011. (j) 
Box-plot quantitative comparison shows that PTEN mRNA expression is down-regulated in PCa tissues that have AR-V7 expression (AR-
V7 positive, n =70), compared with PCa tissues without AR-V7 expression (AR-V7 negative, n = 220), p= 0.023. 
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Elevated expression of AR-V7 contributes to 
increased PIP5K1α and tumor progression
We further characterized the biological 
consequences of AR-V7 overexpression in PCa cells and 
the underlying molecular mechanisms. We introduced 
overexpression of AR-V7 by transfecting non-malignant 
PNT1A cells, which do not express endogenous AR-V7, 
with pEGFP-AR-V7 or pEGFP control vectors. Expression 
of AR-V7 led to an increase in PIP5K1α expression in 
PNT1A cells, as measured by densitometric quantification 
of the blots from three independent experiments using 
Image J (for AR-V7 overexpression, p<0.001; for 
PIP5K1α, p=0.006, Figure 2a and b). This coincided with 
the increased proliferative activity of PNT1A cells that 
expressed AR-V7 vector as compared to the cells that 
expressed control vector (p=0.002, Figure 2c). 
Since 22Rv1 cells represent a cellular model of 
AR-V7 expressing CRPC[14], we therefore examined the 
effect of elevated expression of AR-V7 on PIP5K1α in 
malignant 22Rv1 cells, which harbor AR-V7 and display 
robust growth under castration condition. Consistent with 
the results observed in PNT1A cells, overexpression of 
AR-V7 in 22Rv1 cells significantly increased PIP5K1α 
expression (For AR-V7 overexpression, p<0.001; for 
PIP5K1α, p=0.041, Figure 2d), also led to a significant 
increase in the levels of cyclin E (p<0.001) and cyclin 
A2 (p<0.002), both key determinants of cell proliferation 
(Figure 2e). 
We further assessed whether 22Rv1 cells 
overexpressing AR-V7 may have gained invasive feature 
by using in vivo xenograft mouse model. To this end, 
22Rv1 cells expressing AR-V7 or control vector were 
implanted subcutaneously into the nude mice. Multiple 
tumors were observed in all xenograft mice received 
22Rv1 cells overexpressing AR-V7. The mean tumor 
volume overexpressing AR-V7 was significantly increase 
by 78% as compared with the controls (mean volume for 
pEGFP-control tumors =76.15 mm3, mean volume for 
pEGFP-AR-V7 tumors, the largest one among multiple 
tumors=136.02 mm3, difference=59.87 mm3; 95% 
CI=96.32-175.73; n=6 mice per group, p=0.02, Figure 
2f). Thus, 22Rv1 cells overexpressing AR-V7 gained 
increased ability to grow into multiple tumors as compared 
with the controls. Immuno-histochemical analysis of 
the xenograft tumors revealed a remarkable increase in 
nuclear AR-V7 expression in tumors derived from 22Rv1 
cells expressing AR-V7 (Figure 2g). Tumors derived from 
AR-V7-expressing cells also displayed higher proliferative 
activity, as measured by Ki67-staining (p < 0.001), and 
showed enhanced nuclear PIP5K1α expression (Figure 
2h and 2i). The matrix metalloproteinase (MMP9), a key 
factor that promotes tumor metastasis, was significantly 
higher in tumors derived from AR-V7-expressing cells 
than in the controls as determined by immunoblot analysis 
(p=0.012, Figure 2j). Taken together, AR-V7 promotes 
growth of PCa and induces expression of PIP5K1α in the 
nucleus. This suggests a mechanistic link between AR-V7, 
PIP5K1α and PCa progression. 
PIP5K1α Inhibitor ISA-2011B Suppresses PCa 
Tumor Growth in Xenograft Mouse Models 
Given the mechanistic link we have established 
between AR-V7 and PIP5K1α, we therefore hypothesized 
that AR-V7 cooperates with PIP5K1α to contribute to 
tumor growth, thus treatment of tumors overexpressing 
AR-V7 with ISA-2011B, a selective PIP5K1α inhibitor 
may suppress the tumor growth through blocking the 
deregulated AR-V7 pathways. To investigate this, we 
established 22Rv1 tumors overexpressing AR-V7 in 
mice, and then treated these mice bearing AR-V7-
overexpressing tumors (100-150 mm3 in mean volumes) 
with ISA-2011B or vehicle control. After two weeks of 
treatment, the mean tumor volumes in mice treated with 
ISA-2011B was 3.5-fold smaller compared with those 
treated with vehicle control (mean volume of tumors 
for vehicle-treated controls = 844.12 mm3, and for ISA-
2011B-treated = 243.77 mm3, difference = 600.35 mm3; 
95% CI=96.09-391.44; p=0.014, Figure 3a). We next 
examined the effect of ISA-2011B-treatment on AR-V7 
and the key factors that promote tumor invasiveness in 
the xenograft tumors. Remarkably, AR-V7 expression in 
tumors from the ISA-2011B-treated group was decreased 
by 93% compared to the vehicle-treated controls (p=0.002, 
Figure 3b), and a significant decrease in MMP9 expression 
was also observed as determined by immunoblot analysis 
(p=0.018, Figure 3c). Immunohistochemical analysis 
further revealed a reduction in AR-V7 expression in both 
nucleus and cytoplasm of the tumor cells (Figure 3d). 
Similarly, both nuclear and cytoplasmic expression of 
CDK1 was also decreased in ISA-2011B-treted tumors 
as compared with the controls (Figure 3e). ISA-2011B-
treatment also led to an inhibition in the expression of 
vimentin, a bio-marker for metastatic tumors, in the 
infiltrating tumor cells at the invasive front (Figure 3f). 
Thus, inhibition of PIP5K1α suppresses the growth and 
invasiveness of AR-V7-overexpressing tumors.
Association of AR-V7, PIP5K1α and CDK1 in 
subcellular compartments
The above results suggest that AR-V7, PIP5K1α 
and CDK1 may cooperatively promote tumor progression. 
Immunoprecipitation assays of the nuclear and 
cytoplasmic fractions of 22Rv1 cells further revealed that 
AR-V7 formed complexes with PIP5K1α in the nucleus 
and cytoplasmic compartments (Figure 4a). PIP5K1α in 
turn also formed complexes with CDK1 and AR in both 
nuclear and cytoplasmic compartments of 22Rv1 cells 
(Figure 4a). Thus, AR-V7 may physically interact with 
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Figure 2: The effect of elevated expression of AR-V7 on growth of tumor cells in vitro and in vivo. (a and b). Immunoblots 
show the effect of AR-V7 overexpression on PNT1A cells. Quantification of the blots from three independent experiments is shown in 
the right panel. The mean expression of AR-V7 in cells transfected with pEGFP control vector (Ctrl) was 0 and the mean value in cells 
transfected with pEGFP-AR-V7 (AR-V7) was 4.53 (difference =4.53; 95% CI= 4.28 to 4.78, p<0.001). The mean expression of PIP5K1α 
in cells transfected with pEGFP was set as 1, and the mean value in cells transfected with pEGFP-AR-V7 was 1.13 (difference= 0.13, 95% 
CI=1.06 to 1.21, p=0.006). (c). The effect of AR-V7 expression on proliferation of PNT1A cells was assessed using the non-radioactive MTS 
proliferation assay. Mean absorbance for control PNT1A cells and AR-V7 expressing cells were 0.23 and 0.34 respectively (difference=0.11; 
95% CI=32 to 35, p=0.002). (d and e). Immunoblots show the effect of AR-V7 overexpression on 22Rv1 cells. Overexpression of AR-
V7 increases expression of PIP5K1α, cyclin E and cyclin A2 in 22Rv1cells. For AR-V7, p<0.001 and for PIP5K1α, p=0.041. The mean 
expression of cyclin E1 in control and AR-V7 overexpressing cells were 1 and 2.39 respectively (difference =1.39, 95% CI= 2.35 to 2.44, 
p<0.001). The mean cyclin A2 expression in control and AR-V7 overexpressing cells were 1 and 1.28 respectively (difference=0.28, 95% 
CI=1.21 to 1.35, p=0.002). The above data are presented as average of three or four independent experiments (±SD). *p<0.05, **p<0.01 and 
***p<0.001 are indicated. (f). Growth curves of 22Rv1 tumor xenografts expressing pEGFP-AR-V7 or pEGFP control vector. Difference 
in mean tumor volumes was calculated. p=0.02 on day 22 is indicated. (g, h and i) Tumors from each group were collected at the end of 
experiment, and were subjected to immunohistochemical analysis. Representative microphotographs show the expression of AR-V7, Ki-67 
and PIP5K1α in xenograft tumors. Mean percentages of Ki-67-positive cells in control and AR-V7 overexpressing tumors were 56.17%, 
and 77.05% respectively (difference=20.89%, 95% CI=72.84 to 81.26; P< 0.001). (j) Immunoblots show that mean expression of MMP9 
in control and AR-V7 overexpressing tumors was 36597.43 vs. 48960.61 (difference=12363.17, 95% CI=43375.74 to 54545.47, p=0.012) 
(n= 4 mice/per group). 
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Figure 3: The inhibitory effect of PIP5K1α inhibitor ISA-2011B on growth of 22Rv1 xenograft tumors with elevated 
expression of PIP5K1α and AR-V7 in vivo. (a). Growth of tumor xenografts overexpressing AR-V7 that were treated with vehicle 
(AR-V7 Ctrl) or ISA-2011B at 40 mg/kg (AR-V7 ISA2011B). Treatment ended on day 15. Mean tumor volumes and upper 95% confidence 
intervals are shown. Mean tumor volume of vehicle control group= 844.12 mm3, ISA-2011B treated group = 243.77 mm3 (difference = 
600.35 mm3; 95% CI=96.09-391.44; *P=0.014 on day 15. (b and c). Tumors from each group were collected at the end of experiment. 
Immunoblots show the expression of AR-V7 and MMP9 in tumors from two groups. Mean expression of AR-V7 in vehicle treated vs. 
ISA-2011B treated was 6378.85 and 406.72 (difference=5972.13, 95% CI=214.34 to 599.91, p=0.002; mean MMP9 expression in vehicle 
treated vs. ISA-2011B treated was 48960.61, and 31866.49 (difference=17094.12, p=0.018). (d, e and f). Representative microphotographs 
of immunohistochemical analysis show the expression and cellular localization of AR-V7, CDK1 and Vimentin in vehicle treated tumors 
vs. ISA-2011B treated tumors.
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Figure 4: Evaluation the interconnection among AR-V7, PIP5K1α and CDK1 in the nuclear and cytoplasmic 
compartments of 22Rv1 cells and the mechanisms of the action of ISA2011B on AR-V7. (a). Cytoplasmic (Cyto) and nuclear 
(Nuc) fractions were separated from 22Rv1 cells and were subjected to immunoprecipitation (IP) assay. Antibody to PIP5K1α was used to 
pull down the immunocomplexes, and antibody to IgG was used as a negative control. Antibodies against PIP5K1α, AR-V7, AR and CDK1 
were used for immunoblot analysis (IB). The cell lysates from cytoplasmic and nuclear fractions were used as “Input” controls as indicated 
in the left panel. β-tubulin and lamin B were used as controls for the cytoplasmic vs. nuclear fractions. (b). Evaluation of ISA-2011B-
induced degradation of AR-V7 protein at PIP5K1α-dependent fashion using immunoblot analysis. Expression of PIP5K1α, AR-V7, AR and 
CDK1 was examined in control 22Rv1 cells, and in cells treated with ISA-2011B or MG132 alone, or ISA-2011B and MG132 together. (c, 
d and e). The effect of ISA-2011B on the subcellular expression of AR-V7, AR, PIP5K1α and CDK1 in 22Rv1 cells. The representative 
blots from the same membrane is shown. The expression of these proteins in cytoplasmic (cyto) and nuclear (nuc) compartments of 22Rv1 
cells treated with vehicle control (-) or ISA-2011B (ISA-2011B+). Total cell lysates were used as controls (Total). The blots of β-tubulin 
and Lamin B used as controls were from the same detection as shown in b, c and d. (f). CDK1 was depleted by transfecting 22Rv1 cells 
with CDK1 siRNA or scramble control (Ctrl). The effect of CDK1 knockdown on PIP5K1α and AR-V7 in 22Rv1 cells is analyzed using 
immunoblot analysis. The representative immunoblots from the same membrane were used. The blots of β-tubulin used as controls were 
from the same detection as shown in f. (g and h). The side-by-side comparison of the effect of enzalutamide and ISA-2011B on CDK1 and 
AR-V7. Data is presented as mean of three independent experiments (±SD). ***p < 0.001.
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PIP5K1α, and CDK1 through formation of protein-protein 
complexes. Since AR-V7 forms proteins complexes with 
PIP5K1α, we next investigated whether a decrease in AR-
V7 expression induced by ISA-2011B might be a result 
of disruption of AR-V7/PIP5K1α complexes. To this 
end, we treated 22Rv1 cells with ISA-2011B, MG132, 
a proteasome inhibitor alone or a combination of ISA-
2011B and MG132 together. Expression of PIP5K1α 
was remarkably increased in 22Rv1 cells treated with 
MG132 (Figure 4b), suggesting that MG132 prevented 
proteasome-dependent degradation of PIP5K1α. ISA-
2011B was unable to inhibit PIP5K1α expression in the 
presence MG132 (Figure 4b). This suggests that ISA-
2011B inhibits PIP5K1α expression by disrupting its 
protein stabilization. Interestingly, MG132 treatment 
had no effect on AR-V7 protein stability, however, in the 
presence of MG132, ISA-2011B was unable to supress 
AR-V7 expression (Figure 4b). MG132 did not appear 
to have pronounced effect on protein stabilization of full-
length AR or CDK1 expression (Figure 4b). Thus, ISA-
2011B disrupts stabilization of PIP5K1α and AR-V7/
PIP5K1α complexes, leading to a decrease in AR-V7 
protein expression. This data suggests that ISA-2011B-
induced effect on AR-V7 is specifically dependent on 
PIP5K1α-associated pathways. Next, we examined the 
effect of ISA-2011B on the expression and subcellular 
distribution of AR-V7, PIP5K1α, CDK1 and AR in 
22Rv1 cells. Inhibition of PIP5K1α by ISA-2011B led 
to a remarkable reduction in AR-V7 and CDK1 in both 
nucleus and cytoplasm of 22Rv1 cells (Figure 4c, d and 
e). ISA-2011B treatment also abolished AR expression 
in the nucleus, without depleting the cytoplasmic AR 
(Figure 4c). It has been shown that CDK1 is able to 
phosphorylate AR and is believed to activate AR activity 
during progression of castration resistant PCa[24]. To 
define the functional link between CDK1 and AR-V7, 
we examined effect of inhibition of CDK1 on AR-V7. 
Inhibition of CDK1 via siRNA-mediated knockdown 
led to a remarkable reduction in AR-V7 expression and 
a concomitant decrease in PIP5K1α expression in 22Rv1 
cells (Figure 4f). Similarly, inhibition of PIP5K1α by 
ISA-2011B significantly decreased CDK1 (p<0.001, 
Figure 4g) and AR-V7 in 22Rv1 cells (p<0.001, Figure 
4h), while blocking AR signaling using enzalutamide had 
no inhibitory effect on CDK1 and AR-V7 (Figure 4g and 
h). Taken together, the above findings suggest that AR-V7 
interacts with PIP5K1α and CDK1. Further, abnormal AR-
V7 expression may be effectively inhibited by selectively 
blocking PIP5K1α using its inhibitor ISA-2011B. 
Treatment of 22Rv1cells with ISA-2011B reduces 
expression of AR-V7 signaling complex
PIP5K1α is a central factor that is highly expressed 
in metastatic PCa[15]. As mentioned in Figure 1, both 
PIP5K1α and AR-V7 were highly expressed in metastatic 
tissues from PCa patients. We therefore examined 
whether ISA-2011B might effectively induce apoptosis 
by specifically blocking PIP5K1α/AR-V7/CDK1 in 
PIP5K1α-overexpressing PCa cells. We introduced 
overexpression of PIP5K1α by transfecting of 22Rv1 cells 
with pLPS-EGFP-PIP5K1α or pLPS-EGFP control vector, 
followed by the treatment of the transfected cells with ISA-
2011B or vehicle control. As expected, ISA-2011B was 
effective on both 22Rv1 cells overexpressing PIP5K1α 
(p<0.001) and control cells (p=0.001), and showed more 
pronounced inhibitory effect on cells overexpressing 
PIP5K1α (Figure 5a). ISA-2011B treatment led to a 
significant decrease in AR-V7 expression in both 22Rv1 
cells overexpressing PIP5K1α (p<0.001) and control cells 
(p=0.001, Figure 5b). Overexpression of PIP5K1α greatly 
increased expression of CDK1 and PSA, while ISA-
2011B treatment diminished CDK1 and PSA expression in 
PIP5K1α-overexpressing and control cells (Figure 5c and 
d). The inhibitory effect of ISA-2011B on AR-V7, CDK1 
and PSA was co-incident with a significant induction in 
apoptosis, as determined by PARP activation, in 22Rv1 
cells overexpressing PIP5K1α (p=0.0085) and in controls 
(p=0.0043, Figure 5e). 
The additive effect of combined treatment of 
22Rv1 cells with ISA-2011B and enzalutamide 
Enzalutamide targets ligand-binding domain of AR, 
therefore inhibits AR activity. However, enzalutamide 
has no inhibitory effect on AR-V7 in castration-resistant 
22Rv1 cells [14]. In contrast to enzalutamide, ISA-2011B 
treatment significantly reduces AR-V7 expression in in 
vitro and in vivo PCa models as mentioned above. To 
test the therapeutic potentials of combination therapies 
of ISA-2011B and enzalutamide, we treated 22Rv1 
cells overexpressing PIP5K1α or control vector with 
enzalutmide, ISA-2011B, or combination of enzalutamide 
and ISA-2011B. As expected, ISA-2011B treatment alone 
readily reduced expression of PIP5K1α, AR-V7, CDK1 
and PSA (Figure 6a, b c and d). However, the inhibitory 
effect of a combination of ISA-2011B and enzalutamide on 
PIP5K1α and AR-V7 expression was significantly greater 
than that for ISA-2011B alone (for PIP5K1α, p=0.007; for 
AR-V7, p=0.07, Figure 6b and c). Immunofluorescence 
analysis was performed to visualize the treatment effect 
on AR expression. Enzalutamide greatly reduced the 
cytoplasmic AR, whereas ISA-2011B decreased the 
nuclear AR in 22Rv1 cells. As expected, a combination 
of enzalutamide and ISA-2011B abolished both nuclear 
and cytoplasmic AR expression in 22Rv1 cells, showing a 
greater effect than the single agent (Figure 6e). These data 
suggest that combination treatment using enzalutamide 
and ISA-2011B has an additive effect and completely 
inhibits deregulated AR and AR-V7 mediated pathways. 
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Treatment of metastatic cancer cell lines 
containing PTEN mutation with ISA-2011B and 
enzalutamide in combination
PIP5K1α acts upstream of PI3K/AKT pathways, and 
PTEN status is essential for controlling the proper activity 
of AKT[17]. We therefore next examined the functional 
relationship between ARV-7 and PIP5K1α in PCa cells 
lacking functional PTEN. To this end, PC-3 cells that 
do not express PTEN or AR, but express elevated level 
of pAKTS473, were transfected with pEGFP-AR-V7 
or control vector. Aberrant AR-V7 expression led to 
an increase in PIP5K1α and a concomitant increase in 
pAKTS473 expression, as well as CDK1 on immunoblot 
analysis (Figure 7a and b). Immunoblot analysis was 
performed to assess the effect of enzalutamide, ISA-
2011B, or a combination of ISA-2011B and enzalutamide 
on the expression of PIP5K1α, pAKTS473 and CDK1 
in AR-V7-expressing PC3 cells. ISA-2011B and the 
combination of ISA-2011B and enzalutamide greatly 
inhibited PIP5K1α, pAKTS473 and CDK1 in AR-V7-
expressing PC3 cells (Figure 7a and b). As expected, 
enzalutamide had no inhibitory effect on these proteins 
(Figure 7a and b). Immunofluorescence analysis indicated 
that ISA-2011B alone effectively reduced pAKTS473 
levels in AR-V7-expressing PC3 cells (Figure 7c). ISA-
2011B treatment effectively diminished the expression 
of AR-V7 in both nucleus and cytoplasm of PC3 cells 
(Figure 7c and d). We did not observe a statistically 
significant difference in pAKTS473 or AR-V7 inhibitions 
between the combination of ISA-2011B and enzalutamide 
as compared to ISA-2011B alone in AR-V7-expressing 
PC3 cells (Figure 7a and b). Thus, ISA-2011B alone is 
sufficient to inhibit AR-V7 and pAKT in PTEN- and 
AR-negative PCa cells expressing elevated AR-V7 and 
pAKTS473.
Figure 5: PIP5K1α overexpression and ISA-2011B on AR-V7 in 22Rv1 cells. (a and b). Immunoblots show the effect of 
PIP5K1α overexpression on AR-V7 and the effect of ISA2011B on AR-V7 in 22Rv1 cells expressing PIP5K1α (pLPS-PIP5K1α) or control 
vector (pLPS-Ctrl). Mean expression of PIP51α in vehicle treated and ISA-2011B treated 22Rv1 cells was 1 vs. 0.55 (difference= 0.45 
95% CI=0.47 to 0.64, p=0.001), mean AR-V7 in vehicle treated vs. ISA-2011B treated was 1 vs. 0.31 (difference=0.69, 95% CI=0.16 
to 0.45, p<0.001). Mean PIP5K1α expression in PIP5K1α overexpressing cells treated with vehicle or ISA-2011B was 2.14 vs. 0.65 
(difference=1.50, 95% CI=0.57 to 0.73; p<0.001). Mean AR-V7 expression in PIP51α overexpressing cells treated with vehicle or ISA-
2011B was 0.98 vs. 0.23 (difference= 0.75, 95% CI= 0.15 to 0.31, p<0.001). (c and d). Immunoblots show the effect of ISA-2011B 
on expression of CDK1 and PSA in 22Rv1 cells expressing PIP5K1α or control vectors. (e). ISA2011B induced apoptosis in control 
(p=0.0043) and 22Rv1 cells overexpressing PIP5K1α (p=0.0085), as measured by the expression of the active PARP (cleaved CL. PARP). 
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We next wanted to further study the relationship 
between AR and PIP5K1α/CDK1, and thereby gain 
a deeper understanding of the molecular mechanisms 
underlying the action of ISA-2011B on AR and AR-
V7. We introduced AR expression by transfecting PC3 
cells with pCMV-AR or pCMV control vectors, and 
subsequently treated AR-expressing PC3 cells with ISA-
2011B, enzalutamide, or combination of ISA-2011B and 
enzalutamide. ISA-2011B and a combination of ISA-
2011B and enzalutamide had pronounced inhibitory effect 
on PIP5K1α, pAKTS473, CDK1 in AR-expressing PC3 
cells as compared to control PC3 cells (Figure 7e, 7f and 
7g). 
The interconnection between PIP5K1α and pAKT 
S473 
As mentioned above, ISA-2011B acts on multiple 
cellular pathways. We further validated its specificity 
Figure 6: The effect of combination of enzalutamide and ISA-2011B on PIP5K1α, AR-V7 and AR in 22Rv1 cells 
overexpressing PIP5K1α or control vector. (a). Immunoblot analysis shows the effect of enzalutamide, ISA-2011B and a combination 
of enzalutamide and ISA-2011B on 22Rv1 cells overexpressing PIP5K1α or control vector. (b). The combination of enzalutamide and 
ISA-2011B displays better inhibitory effect on PIP5K1α, as compared to ISA-2011B, *p=0.033. (c). The combination of enzalutamide 
and ISA-2011B displays better inhibitory effect on AR-V7, as compared to ISA-2011B, *p=0.036. Data is presented as average of three 
independent experiments (±SD). (d). The effect of enzalutamide and ISA-2011B alone or in combination on CDK1 and PSA in 22Rv1 cells 
overexpressing PIP5K1α or control vectors. (e). Representative immunofluorescent images show the expression and subcellular localization 
of AR in 22Rv1 cells overexpressing PIP5K1α that were treated with vehicle control, enzalutamide, ISA-2011B and combination of 
enzalutamide and ISA-2011B.
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Figure 7: The interconnection among AR-V7, PIP5K1α, pAKT S473, CDK1 and AR signaling complexes in PCa 
cells harboring PTEN-mutations and the effect of combination of enzalutamide and ISA-2011B on PCa cells with 
PTEN mutations. (a and b). The effect of AR-V7 overexpression on PC3 cells harboring PTEN-muations, and the effect of ISA-2011B, 
enzalutamide and combination of enzalutamide and ISA-2011B on PC3 cells expressing AR-V7. Immunoblots show the expression of 
PIP5K1α, CDK1 and pAKT S473. (c and d). Representative immunofluorescent images of subcellular localization of pAKT S473 and AR-
V7 expression in PC3 cells expressing AR-V7 that were treated with vehicle control (Ctrl), enzalutamide, ISA-2011B and combination of 
enzalutamide and ISA-2011B (ENZ+ISA2011B). The cancer cells are indicated by the arrows. (e and f). The effect of ISA-2011B on PC3 
cells expressing AR. Immunoblots show the expression of PIP5K1α, CDK1 and AR as well as caspase 3 as a marker for apoptosis in vehicle 
treated or ISA-2011B treated PC3 cells expressing control (PCMV) or AR expressing vectors (PCMV-AR). (g). The effect of enzalutamide, 
ISA-2011B and combination of enzalutamide and ISA-2011B on PC3 cells expressing AR. Immunoblots show the expression of PIP5K1α, 
pAKT S473 and CDK1. (h, i and j). The effect of ISA-2011B, LY294002 and combination of ISA-2011B and LY294002 on PIP5K1α, 
pAKT S473 in LNCaP cells. Immunoblots show the expression of PIP5K1α, pAKT S473, P27, AR, PSA and cyclin D1, as well as the 
activation of caspase-3 (cleaved caspase 3). 
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on PIP5K1α-associated PI3K/AKT and AR signaling 
complexes by using PTEN-negative PCa cells expressing 
functional AR. We compared the effect of ISA-2011B with 
LY294002, an inhibitor of PI3K/AKT in PTEN-negative 
LNCaP cells containing functional AR, but expressing 
elevated pAKTS473. We treated LNCaP cells with ISA-
2011B, LY294002 or a combination of ISA-2011B and 
LY294002. ISA-2011B or LY294002 treatment led greatly 
inhibited pAKTS473 and cyclin D1 expression (Figure 
7h, i and j). A combination of ISA-2011B and LY294002 
showed a greater effect, as compared to the single agent, 
to inhibit pAKTS473 and cyclin D1 expression in LNCaP 
cells (Figure 7h and i). This suggests that the action of 
ISA-2011B on PI3K/AKT pathways is similar to that of 
LY294002. However, in striking contrast to LY294002, 
ISA-2011B was able to inhibit AR and PSA expression, 
while LY294002 did not show any effect on AR or PSA 
expression (Figure 7j). A combination of ISA-2011B 
and LY294002 showed similar inhibitory effects as ISA-
2011B alone on AR and PSA (Figure 7j), suggesting that 
LY294002 did not interfere with or augment ISA-2011B. 
In addition, LY294002 treatment reduced p27 expression, 
whereas ISA-2011B showed the opposite effect and 
increased expression of p27, a key cell cycle inhibitor to 
inhibit abnormal proliferation (Figure 7h). The effect of 
ISA-2011B on PIP5K1α-associated PI3K/AKT and AR 
signaling complexes was co-incident its action to induce 
apoptosis as measured by the induction of caspase-3 
Figure 8: A schematic model shows that PIP5K1α acts on two parallel signaling pathways. The model depicts PIP5K1α 
acts on two parallel pathways. PIP5K1α is the key kinase responsible for generation of PIP2. In turns, PIP2 serves as a precursor molecule 
required for PI3K activity and generation of PIP3, thus PIP5K1α acts upstream of PI3K/AKT as illustrated in our previous reported studies 
(Semenas et al., 2014) and the data presented in this study. Here we revealed a new mechanism by which AR-V7 cooperates with PIP5K1α 
and CDK1 to promote growth and invasion of PCa cells. AR-V7 physically interacts with PIP5K1α and CDK1 predominantly in the nucleus 
through formation of protein complexes. In PCa cells with PTEN mutations, AR-V7 is able to increase activity of pAKT. ISA-2011B blocks 
deregulated PIP5K1α/AKT activity and disrupt AR-V7/CDK1/PIP5K1α complexes in the nuclear and cytoplasmic compartment of PTEN-
negative cells. The effect of ISA-2011B on AR may be mediated through CDK1, which is an upstream regulator and co-factor of both AR 
and AR-V7. The combination of ISA-2011B and enzalutamide synergistically inhibits deregulated AR and AR-V7 pathways in PCa cells.
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activity (Figure 7h). These data suggest that ISA-2011B 
acts as PI3K/AKT inhibitor similar to LY294002, but 
also has distinct role act as inhibitor of AR signaling 
complexes.
DISCUSSION
Increasing evidence suggests that AR-V7 is 
involved in development of CRPC, bone metastasis 
and resistance to enzalutamide[5, 7, 8]. However, the 
precise mechanisms and co-factors of AR-V7 that act 
cooperatively to promote progression of CRPC are 
largely unknown. Further, no therapeutic compounds are 
currently available for treatment of patients with PCa 
resistance to enzalutamide. In the present study, we show 
that AR-V7 is highly expressed in metastatic tissues from 
PCa patients and its expression correlates with elevated 
level of PIP5K1α expression in tumor tissues from PCa 
patients. We further demonstrate that overexpression of 
AR-V7 promotes growth and invasiveness of castration-
resistant 22Rv1 tumors in xenograft mice. Overexpression 
of AR-V7 significantly induces cyclin A2, cyclin E and 
MMP9 expression, suggesting that PIP5K1α/AR-V7 may 
act on these target genes, which are in accordance with 
their action on promoting growth and invasiveness of 
PCa in vitro and in vivo. Our findings provide evidence 
suggesting that AR-V7 is functionally associated with 
PIP5K1α. 
In the present study, we show that AR-V7 
physically interacts with PIP5K1α through formation 
of protein-protein complexes. We treated 22Rv1 cells 
with a proteasome inhibitor, MG132 to prevent proteins 
from degradation by proteasome-mediated pathways. 
PIP5K1α protein, but not AR-V7 is no longer degraded 
in the presence of MG132, suggesting that PIP5K1α 
protein stabilization is regulated by proteasome-dependent 
pathways. In the presence of MG132, ISA-2011B was 
unable to inhibit either PIP5K1α or AR-V7. Our finding 
suggests that the stability of AR-V7 protein is dependent 
on its complex-formation with PIP5K1α. Thus, the 
decrease in AR-V7 expression observed in ISA-2011B-
treated cells is a result of disruption of stabilization of 
PIP5K1α/AR-V7 complexes (Figure 8). The precise 
molecular and cellular mechanisms involving the interplay 
among AR-V7, PIP5K1α and their functional targets will 
require further investigation.
In the present study, we show that ISA-2011B 
significantly suppresses growth of castration-resistant 
22Rv1 tumors overexpressing AR-V7 in xenograft mice. 
Our data provide evidence suggesting that the effect of 
ISA-2011B on growth of 22Rv1 tumors is specific, 
and ISA-2011B acts on disruption of PIP5K1α/AR-V7 
complexes, leading to degradation of AR-V7. In addition 
to its role as a potential co-factor to AR-V7 through 
complex-formation, PIP5K1α has a major role as a lipid 
kinase, and acts on PI3K/AKT/PTEN pathways [16]. As 
shown in our previous reported study, PIP5K1α promotes 
invasiveness of PCa cells that lacks functional PTEN and 
AR-V715. In the absence of functional PTEN, PIP5K1α 
induces elevated activation of AKT and promotes PC3 
tumor growth in xenograft mice [15]. In the present study, 
we further show that the effect of ISA-2011B on PI3K/
AKT cascades is comparable to that of LY294002, an 
inhibitor of PI3K/AKT in PTEN-negative LNCaP cells. 
In contrast to LY294002 that is un-related to AR signaling, 
ISA-2011B has a strong inhibitory effect on AR-V7 and 
AR. We further show that the inhibitory effect of ISA-
2011B on AR-V7 or AR is also in part dependent on 
CDK1, and this finding is in agreement with the previous 
reported study [15]. Thus, ISA-2011B has a potential 
therapeutic value for treatment of PCa harboring AR-V7-
related resistance to anti-androgen therapy. 
In the present study, we demonstrate that 
combination of ISA-2011B and enzalutmide have additive 
inhibitory effects on AR signalling in PCa. The second-
generation anti-androgen enzalutamide represents an 
improvement in therapy options for late stage metastatic 
CRPC, however enzalutamide-treated PCa cells rapidly 
develops treatment resistance, most likely attributed 
to the constitutively active AR-V7 [11, 25]. Here, we 
show that treatment of PCa cells with enzalutamide 
diminishes cytoplasmic AR in 22Rv1 cells, suggesting that 
enzalutamide impairs agonist binding whereas ISA-2011B 
eliminates the nuclear AR expression, through PIP5K1α 
and CDK1. As AR interacts with PIP5K1α and CDK1, 
its activity in the nucleus is likely dependent in part on 
PIP5K1α and CDK1 [15]. The combination of ISA-2011B 
and enzalutamide synergistically inhibits deregulated 
AR and AR-V7 pathways in PCa cells. Our data suggest 
a compelling mechanism to circumvent enzalutamide 
treatment.
Taken together, our study identifies novel 
cooperative mechanisms involving PIP5K1α, AR-V7, 
CDK1 and AR, which drive tumor progression and 
contribute to enzalutamide resistance. Our study suggests 
that ISA-2011B and enzalutamide together can suppress 
tumor progression and metastasis through specifically 
blocking multiple pathways including deregulated 
AR pathways and elevated level of AR-V7 signaling 
complexes. Our findings provide new insights into the 
targeted therapeutic approaches to overcome resistance of 
PCa to enzalutamide treatment. 
MATERIALS AND METHODS
Tissue Specimens, Tissue Microarrays and mRNA 
expression data
Tissue microarrays (TMAs) containing primary 
PCa (n=17) and metastatic PCa lesions in distant organs 
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such as lymph node, lung, liver, and bone (n=43) from 
14 PCa patients, and benign prostatic hyperplasia (BPH) 
(n=48) vs. matched PCa tissues (n=48) from 48 patients 
were constructed at Department of Clinical Pathology and 
Cytology, Skåne University Hospital, Malmö. The second 
TMA set that contained BPH and PCa tissues from 48 
patients was purchased from Pantomics Inc. (Richmond, 
CA). The mRNA expression data of PIP5K1A and PTEN, 
and AR-V7 status was extracted from the dataset in the 
cBioPortal database, n= 333 tumors from 425 available 
cases in a prostate cancer patient cohort [26]. The detailed 
information of the data is available at https://tcga-data.
nci.nih.gov/docs/publications/prad_2015/. IlluminaGA 
RNASeq and IlluminaHiseq RNASeq were analyzed [26]. 
The study was approved by the Ethics Committee at Lund 
University and Region Skåne in Sweden. The Helsinki 
Declaration of Human Rights was strictly observed.
Immunohistochemical Analysis
Immunohistochemistry on tumor tissue microarrays 
was performed as previously described [27]. The staining 
procedure was performed using a semiautomatic staining 
machine (Ventana ES, Ventana Inc., Tucson, AZ). The 
sections were viewed under an Olympus BX51 microscope 
at magnification of 20X or 40X. Microphotographs were 
taken by using a high resolution scanner (ScanscopeCS, 
Aperio, Vista, CA). The specimens were evaluated and 
scored by four different scientists, including a pathologist. 
The staining intensity was scored as 0 (negative), 1 
(weakly positive), 2 (moderate positive), 3 (strongly or 
very strongly positive) using an arbitrary semi-quantitative 
scale. The Gleason score 6 was used as cut off to define 
low vs. high grade. 
Cell Culturing and Treatments
The PNT1A cell line was purchased from Sigma 
Aldrich (Stockholm). LNCaP, 22Rv1and PC-3 were 
purchased from American Type Culture Collection 
(Manassas, VA) and were maintained in phenol red-
containing RPMI-1640 medium supplemented with 10% 
fetal bovine serum (FBS), 1% penicillin-streptomycin-
neomycin and 2 mM L-Glutamine (PAA Laboratories, 
GmbH, Austria). For treatment, cells were grown in 
phenol red-free RPMI-1640 medium containing 10% 
charcoal stripped-serum for 24 hours and then were 
treated with drugs alone or in combination for 24 hours 
or 48 hours. Enzalutamide at 5 µM or ISA-2011B at 20 
µM or 50 µM final concentrations or solvent DMSO 1% 
was used. For treatment of 22Rv1 cells with MG132, a 
proteasome inhibitor, cells were treated with MG132 at 
1 µM. For combination treatment of MG132 and ISA-
2011B, cells were pre-treated with MG132 for 30 min at 1 
µM prior to treatment of ISA-2011B. 
Plasmids, Stable Transfection, and siRNA 
Knockdowns
pLPS3-EGFP vector containing full-length human 
PIP5K1α cDNA or control empty vector were used as 
previously described [15]. pEGFP vector containing full-
length AR-V7 and pEGFP vector were used as previously 
described [7]. pCMV-AR containing full-length AR 
and pCMV control vectors were kindly provided by 
Dr. Yvonne Giwercman at Department of Translational 
Medicine, Lund University, Sweden. Transient transfection 
was performed using Lipofectamine® 2000 transfection 
reagent (Life Technologies, Paisley, UK) according to 
the manufacturer’s instructions. SiRNAs against CDK1 
or siRNA negative control duplex were purchased (VWR 
International Inc. Stockholm). SiRNAs (50nM) were 
transfected into 1 x 105 PCa cells using Transfection 
Reagent TransIT-TKO® according to manufacturers’ 
protocol (Mirus Bio LCC). After introduction of respective 
siRNA complexes into PCa cells, cells were then collected 
after 24, 48 and 72 hours post-transfection. 
Mouse Models of Human Xenograft Tumors and 
Treatment 
All animal studies were approved by the Swedish 
Regional Ethical Animal Welfare Committee. Athymic 
NMRI nude male mice (n=6 per experiment group) aged 
8–12 weeks and weighing 25-27 grams each (Taconic 
Europe, Lille Skensved, Denmark) were used in each 
experimental setting. 2x106 cells/mouse in 100 µl sterile 
vehicle solution were implanted subcutaneously into the 
flank. Tumor diameters were measured using calipers, and 
volumes were calculated using the equation (a x b2/2), 
where a and b represent the larger and smaller diameters, 
respectively. Tumors were grown to mean volume of 100-
150 mm3. Xenograft mice with tumors were randomized 
(n=6 mice per group) and treatment of xenograft mice 
with vehicle control, ISA-2011B (40 mg/Kg) was initiated, 
and treatment for every second day was lasted for 15 days. 
The weights of mice were measured regularly and survival 
followed. Tumor samples were collected post-mortem 
and used for immunoblotting and immuno-histochemical 
analyses. 
Proliferation Assay
Proliferation of transfected PNT1A cells 
overexpressing AR-V7 or control vectors were determined 
using MTS proliferation assays (Promega Biotech) 
according to manufacturer’s protocol. Cells at 5 x 103/
well were cultured in 96-well plates for 48 hours. MTS 
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incorporation into the DNA was determined by measuring 
the absorbance on Infinite® M200 multimode microplate 
reader (Tecan Sunrise™).
Immunoblot analysis and source of antibodies 
The cells or tumor tissues were harvested and 
lysed in ice-cold RIPA buffer. Protein (20-30 μg) were 
separated with 12% SDS-PAGE gels and transferred 
onto nitrocellulose membranes. Signals were visualized 
using the Enhanced ChemiLuminescence detection 
system (Pierce, Rockford, USA) and documented with an 
AlphaImager CCD system. Densitometric quantification 
of immunoblots was performed by the ImageJ Image 
Analysis Software (NIH, Baltimore, USA) and represented 
as fold change relative to control and was normalized 
relative to actin or GAPDH bands. The following 
antibodies were used in this study: monoclonal antibodies 
against AR-V7 (produced in JL’s lab) and AR-V7 (Abcam, 
Cambridge, UK), PIP5K1α (Proteintech Inc., and Cell 
Signaling technology), Phosphor-473 AKT (Cell Signaling 
technology and Santa Cruz Biotechnology), p27 (Cell 
signaling technology, Danvers, MA), androgen receptor 
AR (N20) and P27, Cyclin A2 and anti-GAPDH (Santa 
Cruz Biotechnology Inc. CA), PSA and Ki-67 (DAKO, 
Glostrup, Denmark), MMP-9 (Abcam, Cambridge, UK) 
and anti β-Actin (MP Biochemicals, Illkirch, France) 
cyclin E (Upstate Inc.) and Cdk1 (BD Transduction Lab 
Inc.) were used. Secondary antibodies: HRP-conjugated 
anti-mouse IgG and anti-rabbit IgG (GE Healthcare).
Subcellular fractionation and 
Immunoprecipitation
Subcellular fractionation was prepared as previously 
described [28]. For obtaining the nuclear fraction, the 
pellets were incubated in the ice-cold nuclei isolation 
buffer (10 mM HEPES pH 7.9, 1,5 mM MgCl2, 10 mM 
KCl, 0.5 mM DTT, 1 % Triton X-100, 15 % protease 
inhibitor cocktail Complete Mini, 1 mM PMSF). 
After the separation steps, the nuclear and cytoplasmic 
fractions were obtained and subjected to immunoblot 
analysis. Antibodies against β-tubulin and Lamin B 
were used to validate the purity of the cytoplasmic and 
nuclear fractions, respectively. For immunoprecipitation 
(IP) assay, antibody against PIP5K1α was used to pull 
down the immunocomplexes, and antibody to IgG (BD 
Biosciences, San Jose, CA, USA) was used as a negative 
control. 500 μg of freshly prepared protein lysates were 
incubated with the antibody of interests and 30 μl of 
G-sepharose beads (GE Healthcare) for 3 hours at 4 
°C. The samples were then washed in RIPA buffer and 
subjected to immunoblot analysis. 
Immunofluorescence analysis 
PCa cells were grown on the glass coverslips in 
phenol red-free RPMI-1640 medium containing 10% 
charcoal stripped-serum for 24 hours and were then 
treated with the indicated drugs for 24 hours. Cells were 
fixed with 4% paraformaldehyde in PBS. For blocking 
background staining from nonspecific interactions, Image-
iT™ FX signal enhancer (Molecular Probes, Inc) was 
used. Primary antibodies against Phosphor-473 AKT, AR 
and AR-V7 were used. The secondary antibodies including 
rabbit anti-donkey conjugated to Rhodamine (Chemicon/
Millipore International Inc, Temecula, CA, USA) or anti-
goat conjugated to FITC antibodies at 1:200 and goat anti-
rabbit Alexa Fluor 488 at 1:500 (Invitrogen, Stockholm, 
Sweden) were used. 4′,6-Diamidino-2-phenylindole 
counterstain (SERVA Electrophoresis GmbH, Heidelberg, 
Germany) was used to visualize cell nuclei. The slides 
were detected under an Olympus AX70 fluorescent 
microscope (Nikon DS-U1, Stockholm, Sweden). 
The software ACT2U was used (ACT2U version. 1.5, 
Stockholm, Sweden). 
Statistical Analysis 
Tukey-test, ANOVA, Mann-Whitney test, student 
t-test and Spearman rank correlation tests were performed. 
All outcome variables are representative of at least three 
independent experiments. All statistical testes were two-
sided, and p values less than 0.05 were considered to be 
statistical significant. Statistical software, Social Sciences 
software (SPSS, version 21, Chicago), was used.
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